Part 3/8:
The FDA has issued warnings demanding these companies cease making false claims on their websites. Specifically, Hims and Hers was accused of falsely asserting that their products contain the same active ingredients found in FDA-approved drugs, a claim that could mislead consumers into believing they are receiving legitimate, regulated medications. The regulatory agency emphasized the importance of transparency and adherence to medical guidelines in telehealth marketing practices.